Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001104659-25-119323·CRESCENT BIOPHARMA, INC.
Schedule 13D ownership disclosure
CRESCENT BIOPHARMA INC.
Ordinary Shares, $0.001 par value · CUSIP: G2545C104
Event date: 2025-12-04
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Fairmount Funds Management LLCReported CIK 0001802528
Shares: 5,643,482.00 · Class: 18.53%
- Fairmount Healthcare Fund II L.P.Reported CIK 0001769651
Shares: 5,643,482.00 · Class: 18.53%
- Peter Evan HarwinReported CIK 0001663607
Shares: 5,643,482.00 · Class: 18.53%
- Tomas KiselakReported CIK 0001830177
Shares: 5,643,482.00 · Class: 18.53%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-119323
- Form type
- SCHEDULE 13D/A
- Filer
- CRESCENT BIOPHARMA, INC.
- CIK
- CIK 1253689
- Filed
- Dec 08, 2025
- Reporting period
- Dec 04, 2025
- Description
- Schedule 13D beneficial ownership